A detailed history of Newbridge Financial Services Group, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Newbridge Financial Services Group, Inc. holds 200 shares of CRSP stock, worth $9,576. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Previous 776 74.23%
Holding current value
$9,576
Previous $41,000 78.05%
% of portfolio
0.0%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$44.62 - $62.75 $25,701 - $36,144
-576 Reduced 74.23%
200 $9,000
Q1 2024

Apr 24, 2024

SELL
$60.67 - $89.12 $18,201 - $26,736
-300 Reduced 27.88%
776 $52,000
Q4 2023

Mar 28, 2024

BUY
$38.62 - $72.18 $13,825 - $25,840
358 Added 49.86%
1,076 $67,000
Q3 2023

Oct 17, 2023

BUY
$45.39 - $59.0 $9,078 - $11,800
200 Added 38.61%
718 $32,000
Q3 2022

Oct 13, 2022

BUY
$61.1 - $83.78 $122 - $167
2 Added 0.39%
518 $34,000
Q2 2022

Jul 15, 2022

SELL
$43.23 - $73.83 $14,568 - $24,880
-337 Reduced 39.51%
516 $31,000
Q1 2022

Apr 26, 2022

BUY
$53.19 - $79.24 $15,318 - $22,821
288 Added 50.97%
853 $54,000
Q4 2021

Jan 19, 2022

BUY
$70.09 - $111.29 $19,555 - $31,049
279 Added 97.55%
565 $43,000
Q3 2021

Oct 27, 2021

BUY
$110.2 - $156.64 $5,620 - $7,988
51 Added 21.7%
286 $32,000
Q1 2021

Sep 07, 2021

SELL
$110.72 - $210.04 $127,328 - $241,546
-1,150 Reduced 83.03%
235 $29,000
Q4 2020

Sep 07, 2021

SELL
$79.67 - $173.23 $20,634 - $44,866
-259 Reduced 15.75%
1,385 $212,000
Q3 2020

Sep 07, 2021

BUY
$78.5 - $100.64 $129,054 - $165,452
1,644 New
1,644 $138,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Newbridge Financial Services Group, Inc. Portfolio

Follow Newbridge Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.